Frontiers16d
Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy
Although low-molecular-weight heparin (LMWH) has been recommended to prevent venous ... The KyberSept trial found that high-dose antithrombin III therapy had no effect on 28-day all-cause mortality in ...
Frontiers16d
Is it time to switch to bivalirudin for ECMO anticoagulation?
For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct ...
BMJ16d
Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)
The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with ...
Medscape11y
Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated With Intravenous Unfractionated Heparin
Background: Both the activated partial thromboplastin time (aPTT) and anti-Xa assay can be used to monitor unfractionated heparin (UFH). Following implementation of an anti-Xa method for heparin ...
Medscape17y
Current Issues in Heparin Dosing
VTE a 80 units/kg bolus; 18 units/kg/h infusion ACS b 60-70 units/kg bolus (max 5000 units); 12-15 units/kg/h (max 1000 units/h) infusion Acute STEMI c with rtPA d 60 units/kg bolus (max 4000 ...